Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cephalexin + metronidazole is a combination of two antibiotics used together to treat mixed bacterial infections, particularly those involving both aerobic and anaerobic bacteria. Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, primarily targeting gram-positive organisms. Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa; it works by disrupting DNA synthesis in susceptible organisms. This combination may be used empirically for polymicrobial infections such as intra-abdominal or pelvic infections where both aerobic and anaerobic pathogens are suspected[4][5][6]. The drugs act via distinct mechanisms, providing broad-spectrum antibacterial coverage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cephalexin + metronidazole.